Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SIGLEC15 antibody (AA 22-319)

This Rabbit Polyclonal antibody specifically detects SIGLEC15 in ELISA, WB, FACS, IF and ICC. It exhibits reactivity toward Human.
Catalog No. ABIN7872317
$625.62
Plus shipping costs $50.00
100 μg
Shipping to: United States
Delivery in 2 to 4 Business Days

Quick Overview for SIGLEC15 antibody (AA 22-319) (ABIN7872317)

Target

See all SIGLEC15 Antibodies
SIGLEC15 (Sialic Acid Binding Ig-Like Lectin 15 (SIGLEC15))

Reactivity

  • 48
  • 13
  • 3
  • 2
Human

Host

  • 30
  • 13
  • 9
Rabbit

Clonality

  • 27
  • 21
  • 2
Polyclonal

Conjugate

  • 26
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This SIGLEC15 antibody is un-conjugated

Application

  • 18
  • 17
  • 12
  • 8
  • 4
  • 3
  • 2
  • 1
  • 1
  • 1
ELISA, Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunocytochemistry (ICC)
  • Binding Specificity

    • 8
    • 6
    • 5
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 22-319

    Purpose

    SIGLEC15 Antibody / Sialic acid-binding Ig-like lectin 15

    Purification

    Immunogen affinity purified

    Immunogen

    E.coli-derived human SIGLEC15 recombinant protein (Position: R22-R319) was used as the immunogen for the SIGLEC15 antibody.

    Isotype

    IgG
  • Application Notes

    Optimal dilution of the SIGLEC15 antibody should be determined by the researcher.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

    Buffer

    Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

    Storage

    4 °C,-20 °C

    Storage Comment

    After reconstitution, the SIGLEC15 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
  • Target

    SIGLEC15 (Sialic Acid Binding Ig-Like Lectin 15 (SIGLEC15))

    Alternative Name

    SIGLEC15

    Background

    SIGLEC15 antibody recognizes Sialic acid-binding Ig-like lectin 15, a type I transmembrane protein belonging to the Siglec (sialic acid-binding immunoglobulin-like lectins) family of immune modulators. SIGLEC15 plays an important role in immune regulation, osteoclast differentiation, and tumor immune evasion. It binds sialylated glycoconjugates on target cells, transmitting inhibitory or activating signals that shape immune responses. The SIGLEC15 antibody is widely used in immunology, oncology, and bone biology research to study checkpoint signaling and macrophage-mediated immune regulation.

    Sialic acid-binding Ig-like lectin 15 is encoded by the SIGLEC15 gene located on human chromosome 18q12.3. The protein consists of an extracellular N-terminal V-set immunoglobulin domain that recognizes sialylated glycans, a transmembrane segment, and a short cytoplasmic tail that associates with adaptor proteins such as DAP12 or DAP10 to mediate downstream signaling. In osteoclasts, SIGLEC15 promotes differentiation and bone resorption by activating phosphoinositide 3-kinase and mitogen-activated protein kinase cascades. In immune cells, it functions as a checkpoint ligand that suppresses T-cell activation, analogous to PD-L1.

    Studies using the SIGLEC15 antibody have shown that this protein is upregulated on tumor-associated macrophages and osteoclasts in various malignancies and inflammatory diseases. Western blot analyses typically detect a 35-40 kilodalton glycoprotein band. Immunohistochemistry demonstrates strong membrane staining in macrophage-rich regions of tumors and in bone-resorptive zones. Functionally, SIGLEC15 acts as an immune suppressor by binding unidentified receptors on T cells and natural killer cells, inhibiting cytokine production and cytotoxic responses. Its expression inversely correlates with PD-L1, suggesting a complementary role in immune evasion mechanisms exploited by tumors.

    Therapeutic targeting of SIGLEC15 has emerged as a promising strategy in cancer immunotherapy, particularly for patients unresponsive to PD-1/PD-L1 blockade. The protein also regulates osteoclast activity and bone remodeling, making it relevant in osteoporosis and arthritis research. NSJ Bioreagents provides a validated SIGLEC15 antibody optimized for western blot, flow cytometry, and immunohistochemistry. This reagent enables researchers to investigate innate immune regulation, tumor microenvironment biology, and checkpoint-based immunotherapy development.

    UniProt

    Q6ZMC9
You are here:
Chat with us!